Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 63

Sort by

Sort Order Select

Journal Articles

Safety and efficacy of IL-6 knockdown anti-CD19 CAR-T cells (ssCART-19) in the treatment of primary/secondary central nervous system lymphoma

Blood (2025) 146 (Supplement 1): 927.

https://doi.org/10.1182/blood-2025-927

Published: 2025

Journal Articles

Glofitamab effectively bridging CD19-specific CAR T- cell therapy while maintaining safety in patients with refractory DLBCL

Lili Zhou, Botao Wang, Ping Li, Yan Lu, Shiguang Ye, Shaoguang Li, Aibin Liang

Blood (2025) 146 (Supplement 1): 7265.

https://doi.org/10.1182/blood-2025-7265

Published: 2025

Journal Articles

Efficacy and safety of chidamide and Bruton tyrosine kinase inhibitors combination therapy in relapsed/refractory diffuse large B-cell lymphoma

Lili Zhou, Bing Li, Shiguang Ye, Yan Lu, Shaoguang Li, Ping Li

Blood (2025) 146 (Supplement 1): 3700.

https://doi.org/10.1182/blood-2025-3700

Published: 2025

Journal Articles

Exploring molecular heterogeneity and clonal evolution in chronic myelomonocytic leukemia via single-cell transcriptome sequencing

Jie Zhou, Yuyuan Huang, Hao Wu, Bing Li, Shaoguang Li, Aibin Liang, Jianfei Fu

Blood (2025) 146 (Supplement 1): 6763.

https://doi.org/10.1182/blood-2025-6763

Published: 2025

Journal Articles

A New Prognostic Scoring Model in Myelodysplastic Neoplasms

Baoqing Yang, Jie Zhou, Hao Wu, Shaoguang Li, Aibin Liang, Jianfei Fu

Blood (2024) 144 (Supplement 1): 6702.

https://doi.org/10.1182/blood-2024-202368

Published: 2024

Journal Articles

p53 Immunohistochemistry As a High-Specificity Biomarker to Predict Allelic State and Overall Survival in Myelodysplastic Syndrome or Acute Myeloid Leukemia with Mutated TP53

Shyam Ajay Patel, Salwa Khedr, Caroline D Gordon, Noah Littman, Bruce Woda, Lloyd Hutchinson, Jan Cerny, Shaoguang Li, William Selove, Jonathan M. Gerber

Blood (2024) 144 (Supplement 1): 1546.

https://doi.org/10.1182/blood-2024-209416

Published: 2024

Journal Articles

BTK Inhibitors and Chidamide-Combined Therapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma with MYC +

Lili Zhou, Shiguang Ye, Ping Li, Bing Li, Yan Lu, Shaoguang Li, Aibin Liang

Blood (2024) 144 (Supplement 1): 6524.

https://doi.org/10.1182/blood-2024-208414

Published: 2024

Journal Articles

ITGB3 Promotes the Progression of JAK2V617F-Positive Myeloproliferative Neoplams By Regulating Calreticulin to Inhibit Cellular Autophagy

Jie Zhou, Wenjun Zhang, Baoqing Yang, Hao Wu, Bing Li, Shaoguang Li, Aibin Liang, Jianfei Fu

Blood (2023) 142 (Supplement 1): 2748.

https://doi.org/10.1182/blood-2023-181816

Published: 2023

Journal Articles

Development and Validation of a Clinical Prediction Model for the Efficacy of CD19 CAR T-Cell Therapy in DLBCL

Bin Xue, Xiu Luo, Yifan Liu, Lili Zhou, Shiguang Ye, Shaoguang Li, Ping Li, Aibin Liang

Blood (2023) 142 (Supplement 1): 2142.

https://doi.org/10.1182/blood-2023-184885

Published: 2023

Journal Articles

CAR T-Cell Therapy Combined with PD-1 Inhibitors Significantly Improve the Efficacy and Prognosis of r/r DLBCL with TP53 Alterations

Bin Xue, Xiu Luo, Yifan Liu, Shiguang Ye, Lili Zhou, Shaoguang Li, Ping Li, Aibin Liang

Blood (2023) 142 (Supplement 1): 3515.

https://doi.org/10.1182/blood-2023-180500

Published: 2023

Journal Articles

The Efficacy and Safety of Decitabine Combined with Fludarabine and Cyclophosphamide As Conditioning Regimen in Second CD19 CAR-T Infusion

Shiguang Ye, Lili Zhou, Yan Lu, Xiu Luo, Shaoguang Li, Ping Li, Aibin Liang

Blood (2023) 142 (Supplement 1): 6882.

https://doi.org/10.1182/blood-2023-184765

Published: 2023

Journal Articles

Zanubrutinib Combined Regimen As Bridging Treatment on Promising Clinical Outcome of CD19 Chimeric Antigen Receptor T-Cell Therapies in Relapsed or Refractory Large B-Cell Lymphoma

Yan Lu, Shiguang Ye, Lili Zhou, Ping Li, Shaoguang Li, Aibin Liang

Blood (2023) 142 (Supplement 1): 6925.

https://doi.org/10.1182/blood-2023-182763

Published: 2023

Journal Articles

Radiotherapy Combined Chimeric Antigen Receptor T-Cells Therapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma（R/R DLBCL）

Lili Zhou, Yifan Liu, Shiguang Ye, Ping Li, Shaoguang Li, Aibin Liang

Blood (2023) 142 (Supplement 1): 3137.

https://doi.org/10.1182/blood-2023-184352

Published: 2023

Journal Articles

Characterization of Hemophagocytic Lymphohistio(HLH）in Relapsed Diffuse Large B-Cell Lymphoma Patients after CAR-T Therapy

Lili Zhou, Shiguang Ye, Xiuyong Dang, Shaoguang Li, Ping Li

Blood (2023) 142 (Supplement 1): 6276.

https://doi.org/10.1182/blood-2023-186563

Published: 2023

Journal Articles

Clinical Characteristics of Long-Term Survivors Treated with BCMA CAR T Cell

Fangce WANG, Bing Li, Ping Li, Shiguang Ye, Lili Zhou, Wenjun Zhang, Shaoguang Li, Aibin Liang

Blood (2023) 142 (Supplement 1): 6865.

https://doi.org/10.1182/blood-2023-185161

Published: 2023

Journal Articles

To Investigate the Efficacy of Long-Term Step-Reduction Methylprednisolone in the Treatment of Severe Persistent Thrombocytopenia after CAR-T Cell Therapy

Haiyan Jiang, Ping Li, Lili Zhou, Shiguang Ye, Xiu Luo, Yan Lu, Bin Xue, Shaoguang Li, Aibin Liang

Blood (2023) 142 (Supplement 1): 6934.

https://doi.org/10.1182/blood-2023-188386

Published: 2023

Journal Articles

BTK Inhibitors and Chidamide-Combined Therapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Lili Zhou, Shiguang Ye, Ping Li, Bing Li, Shaoguang Li, Aibin Liang

Blood (2023) 142 (Supplement 1): 6258.

https://doi.org/10.1182/blood-2023-180524

Published: 2023

Journal Articles

YBX1 is required for maintaining myeloid leukemia cell survival by regulating BCL2 stability in an m 6 A-dependent manner

Blood (2021) 138 (1): 71–85.

https://doi.org/10.1182/blood.2020009676

Published: 2021

Includes: Supplemental data

Journal Articles

Activation of JAK2/STAT5 Pathway Reduces Expression Level of DNMT3a in MPN Cell Line

Jie Zhou, Aibin Liang, PhD, Shaoguang Li, Wenjun Zhang, Jianfei FU, MD

Blood (2019) 134 (Supplement_1): 5394.

https://doi.org/10.1182/blood-2019-125434

Published: 2019

Journal Articles

Clinical Presentation, Management and Biomarkers of Cytokine Release Syndrome after Anti-CD19 CART-Cell Therapy for r/r ALL

Ping Li, Lili Zhou, Shiguang Ye, Shaoguang Li, Aibin Liang, MD PhD

Blood (2019) 134 (Supplement_1): 5625.

https://doi.org/10.1182/blood-2019-130119

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Safety and efficacy of IL-6 knockdown anti-CD19 CAR-T cells (ssCART-19) in the treatment of primary/secondary central nervous system lymphoma

Glofitamab effectively bridging CD19-specific CAR T- cell therapy while maintaining safety in patients with refractory DLBCL

Efficacy and safety of chidamide and Bruton tyrosine kinase inhibitors combination therapy in relapsed/refractory diffuse large B-cell lymphoma

Exploring molecular heterogeneity and clonal evolution in chronic myelomonocytic leukemia via single-cell transcriptome sequencing

A New Prognostic Scoring Model in Myelodysplastic Neoplasms

p53 Immunohistochemistry As a High-Specificity Biomarker to Predict Allelic State and Overall Survival in Myelodysplastic Syndrome or Acute Myeloid Leukemia with Mutated TP53

BTK Inhibitors and Chidamide-Combined Therapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma with MYC +

ITGB3 Promotes the Progression of JAK2V617F-Positive Myeloproliferative Neoplams By Regulating Calreticulin to Inhibit Cellular Autophagy

Development and Validation of a Clinical Prediction Model for the Efficacy of CD19 CAR T-Cell Therapy in DLBCL

CAR T-Cell Therapy Combined with PD-1 Inhibitors Significantly Improve the Efficacy and Prognosis of r/r DLBCL with TP53 Alterations

The Efficacy and Safety of Decitabine Combined with Fludarabine and Cyclophosphamide As Conditioning Regimen in Second CD19 CAR-T Infusion

Zanubrutinib Combined Regimen As Bridging Treatment on Promising Clinical Outcome of CD19 Chimeric Antigen Receptor T-Cell Therapies in Relapsed or Refractory Large B-Cell Lymphoma

Radiotherapy Combined Chimeric Antigen Receptor T-Cells Therapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma（R/R DLBCL）

Characterization of Hemophagocytic Lymphohistio(HLH）in Relapsed Diffuse Large B-Cell Lymphoma Patients after CAR-T Therapy

Clinical Characteristics of Long-Term Survivors Treated with BCMA CAR T Cell

To Investigate the Efficacy of Long-Term Step-Reduction Methylprednisolone in the Treatment of Severe Persistent Thrombocytopenia after CAR-T Cell Therapy

BTK Inhibitors and Chidamide-Combined Therapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

YBX1 is required for maintaining myeloid leukemia cell survival by regulating BCL2 stability in an m 6 A-dependent manner

Activation of JAK2/STAT5 Pathway Reduces Expression Level of DNMT3a in MPN Cell Line

Clinical Presentation, Management and Biomarkers of Cytokine Release Syndrome after Anti-CD19 CART-Cell Therapy for r/r ALL

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only